Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 476Carcinoma, Hepatocellular 131Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 62Pancreatic Neoplasms 54Liver Neoplasms 44Stomach Neoplasms 37Neoplasms 37Esophageal Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Colorectal Cancer Metastatic 19Ovarian Neoplasms 15Gastrointestinal Neoplasms 14Breast Neoplasms 13Biliary Tract Neoplasms 13Adenocarcinoma 11Lung Neoplasms 10Carcinoma, Renal Cell 10Digestive System Neoplasms 9Cholangiocarcinoma 9Intestinal Neoplasms 8Melanoma 7Gallbladder Neoplasms 7Glioblastoma 6Endometrial Neoplasms 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Sarcoma 5Prostatic Neoplasms 5

Interventions

S 1 (combination) 2tislelizumab 1sintilimab 1Paclitaxel 1Hyperthermic Intraperitoneal Chemotherapy 1Doxorubicin 1Cisplatin 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric Cancer Peritoneal Metastases × Bevacizumab × Gastrointestinal × Clear all
NCT06487715 2024-07-05

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
42 enrolled
Gastrointestinal

Gastric Cancer Peritoneal Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡